<DOC>
	<DOCNO>NCT00258245</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Ascorbic acid may help arsenic trioxide work well make cancer cell sensitive drug . Bortezomib may stop growth cancer cell block enzymes need cell growth . Thalidomide may stop growth cancer cell stop blood flow cancer . Giving arsenic trioxide ascorbic acid together bortezomib , thalidomide , dexamethasone may stop growth kill cancer cell . PURPOSE : This phase I trial study side effect best dose arsenic trioxide give together ascorbic acid , bortezomib , thalidomide , dexamethasone treat patient relapsed refractory multiple myeloma plasma cell leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Ascorbic Acid Combined With Bortezomib , Thalidomide , Dexamethasone Treating Patients With Relapsed Refractory Multiple Myeloma Plasma Cell Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity arsenic trioxide give combination ascorbic acid , bortezomib , thalidomide , dexamethasone , particularly term sensory neuropathy , patient relapse refractory multiple myeloma plasma cell leukemia . Secondary - Determine overall response rate , complete response rate , response duration patient treat maximum tolerated dose regimen . - Determine whether addition arsenic trioxide ascorbic acid treatment regimen ( begin course 2 ) increase NFKB inhibition patient course 2 3 compare course 1 . OUTLINE : This multicenter , dose-escalation study arsenic trioxide . - Induction therapy : Patients receive bortezomib IV 3-5 second dexamethasone IV orally day 1 , 4 , 8 , 11 oral thalidomide daily day 1-21 ( course 1 ) . For course 2 subsequent course , patient receive arsenic trioxide IV 1-2 hour , ascorbic acid IV 15 minute , bortezomib IV 3-5 second , dexamethasone IV orally day 1 , 4 , 8 , 11 thalidomide daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve plateau response proceed maintenance therapy . - Maintenance therapy : Patients receive oral dexamethasone every day oral thalidomide daily absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Aspirin , aluminum hydroxide , magnesium hydroxide drug combination</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma ( MM ) plasma cell leukemia meet 1 follow criterion : Relapsed refractory disease treatment prior effective therapy Exhibited &lt; partial response last therapy Measurable disease , define 1 following : Serum M protein ≥ 1.0 g/dL Urine Mprotein ≥ 500 mg/24 hour Plasmacytoma bidimensional measurement CT scan MRI ( axis ≥ 1 cm ) Previously treat ≥ 1 induction chemotherapy regimen MM No known CNS involvement multiple myeloma PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod SWOG 02 OR Karnofsky 60100 % Life expectancy More 12 week Hematopoietic WBC ≥ 1,500/mm^3 Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 80,000/mm^3 Hemoglobin ≥ 8.5 g/dL No history heparininduced thrombocytopenia Low blood count allow marrow heavily infiltrate multiple myeloma Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Renal Creatinine ≤ 2.5 mg/dL Cardiovascular QTc &lt; 480 msec EKG presence serum potassium ≥ 4.0 mEq/dL serum magnesium ≥ 1.8 mg/dL LVEF ≥ 55 % ECHO MUGA No prior deep vein thrombosis , unless concurrent anticoagulation No symptomatic congestive heart failure No unstable angina pectoris No history ventricular arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No history allergic reaction severe adverse reaction attribute compound similar chemical biological composition study drug No malignancy past 2 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix No peripheral neuropathy ≥ grade 2 No ongoing active infection require IV antibiotic No psychiatric illness social situation would preclude study compliance No uncontrolled illness Controlled HIV disease allow long associate comorbid complication No active peptic ulcer disease No condition would confer high risk bleeding complication PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior thalidomide lenalidomide MM Prior autologous allogeneic stem cell transplant MM allow Concurrent hematopoietic growth factor ( e.g. , epoetin alfa , filgrastim [ GCSF ] ) MM allow Chemotherapy See Disease Characteristics More 4 week since prior arsenic trioxide MM Endocrine therapy More 4 week since prior corticosteroid MM Radiotherapy More 4 week since prior therapeutic radiotherapy ( e.g. , plasmacytoma ) Palliative radiotherapy painful symptomatic lytic skeletal lesion allow within past 4 week Surgery Not specify Other More 4 week since prior cytotoxic agent therapy ( e.g. , bortezomib ) MM More 30 day ( 5 halflives ) since prior investigational agent Concurrent bisphosphonates MM allow No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
</DOC>